Research Out of Mexico Demonstrates Efficacy of Medical Marijuana’s (MJNA) RSHO-X™
Ryan Allway
October 19th, 2016
News, Top News
Medical Marijuana Inc. (OTC: MJNA) received further validation of its Real Scientific Hemp Oil-X™ (“RSHO-X™”) after Dr. Carlos G. Aguirre Velazquez released a new study conducted on children with refractory epilepsy. In the study, he reported 60% of 53 children treated with cannabidiol (“CBD”) oil experienced a reduction in seizures, including 16% that were completely free of seizures and 51% that experienced a moderate to important improvement.
“This is such exciting news for our company and we are honored and humbled to witness this new work performed by Dr. Velazquez,” said Medical Marijuana, Inc.’s Chief Executive Officer Dr. Stuart Titus. “We are proud to be the first company with CBD products approved by the Mexico government, and thrilled to see the results that our products are producing for the quality of life for families that otherwise had no options.”
In this article, we will take a closer look at these study results and why they could translate into a significant opportunity for the company, its shareholders, and those suffering from epilepsy.
Securing an Import License
Medical Marijuana, Inc. secured the right to import its RSHO-X™ CBD oil into Mexico in early February 2016 when the Health Department of Mexico (“COFEPRIS”) issued the country’s first-ever government permits for a medicinal cannabis product. The move followed a series of Congressional hearings in January where the company joined other advocates in Mexico City to lobby for the legalization of the drug for treating numerous serious medical conditions.
The market for cannabinoid-based treatments in Mexico could be roughly the same size as California’s enormous market – and President Pena Nieto has already proposed legalizing medical marijuana and easing limits for personal use of the drug. In late 2015, the Mexican Supreme Court also ruled that marijuana for recreational use could be legalized under the Constitution, which could pave the way for a dramatically changed market.
In addition to Mexico, the company has been successful in securing the rights to import its CBD oils into a number of other countries around the world, including Paraguay, Brazil, and Puerto Rico. These licenses permit the import of RSHO™ to treat a growing number of medical indications, including epilepsy, Parkinson’s disease, chronic pain, and cancer pain and related symptoms – a much more diverse array than prescription cannabinoids.
Promising Study Results
Dr. Carlos G. Aguirre Velazquez’s study showed promising results when it comes to using CBD oils to treat children with refractory epilepsy. Of the 53 children included in the study, 16% reported no more seizures at all, while 60% reported a reduction in seizures. In addition, 83% reported improvements in emotions, 88% saw improved cognition, 77% reported better sleep, and 60% had improved feeding, suggesting strong improvements in quality of life.
These results confirm similar findings by other companies studying the effects of cannabinoids on medical conditions like epilepsy. For instance, GW Pharmaceuticals plc’s (NASDAQ: GWPH) Epidiolex is a cannabinoid that has been approved in several countries for the treatment of seizures with a 36.5% reduction in monthly motor seizures. A number of other companies are similarly developing and studying drugs targeting epilepsy and related conditions.
Interestingly, Dr. Aguirre Velazquez’s RSHO-X™ study found no adverse side-effects among the 53 children enrolled in the study, compared to nearly 80% of Epidiolex that reported issues. These side-effects included decreased appetite (19%), diarrhea (19%), fatigue (13%) and convulsion (11%). In the GW Pharmaceuticals study, serious events were reported in nearly a third of the patients, while 3% of those enrolled ended up discontinuing treatments because of these effects.
Looking Ahead
Medical Marijuana Inc. represents a compelling opportunity for investors interested in the cannabis industry. With growing distribution of its RSHO-X™ CBD oils, the company has the opportunity to reach a wide market of patients without conducting expensive clinical trials. The botanical version of CBD may also have fewer side-effects and similar efficacy profiles compared to pharmacological versions based on Dr. Aguirre Velazquez’s research.
For more information, visit the company’s website at www.medicalmarijuanainc.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Valens GroWorks is a multi-licensed, vertically integrated provider of Canadian cannabis products with two wholly-owned subsidiaries located in Kelowna, BC.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
